Identification of Key Blood Molecular Markers for Immunotherapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00507702 |
Recruitment Status
:
Suspended
(Improving assay methods)
First Posted
: July 26, 2007
Last Update Posted
: July 9, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Squamous Cell Carcinoma Adenocarcinoma Neoplasms | Procedure: phlebotomy |
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Identification of Key Blood Molecular Markers for Immunotherapy |
Study Start Date : | July 2006 |
Estimated Primary Completion Date : | July 2012 |
Estimated Study Completion Date : | July 2012 |
-
Procedure: phlebotomy
- To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.
- Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.
- Normal volunteers who do not have cancer or other medical conditions that may affect survival.
Exclusion Criteria:
- Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.
- Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.
- Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00507702
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Jeffrey A. Norton | Stanford University |
Responsible Party: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00507702 History of Changes |
Other Study ID Numbers: |
VAR0017 97125 ( Other Identifier: Stanford University Alternate IRB Approval Number ) VAR0017 ( Other Identifier: Stanford University ) |
First Posted: | July 26, 2007 Key Record Dates |
Last Update Posted: | July 9, 2012 |
Last Verified: | July 2012 |
Additional relevant MeSH terms:
Carcinoma, Squamous Cell Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell |